# Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

> **NCT00437216** · — · COMPLETED · sponsor: **Galderma R&D** · enrollment: 2488 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Clobetasol Propionate, 0.05%
- **DRUG:** Clobetasol propionate, 0.05% Spray

## Key facts

- **NCT ID:** NCT00437216
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 2488 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437216, "Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00437216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*